Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently has eight commercial rare disease products and five additional product candidates in late-stage development. Eton's business model centers on identifying, acquiring, and advancing products through the development and regulatory process, leveraging its business development experience, regulatory expertise, particularly within the 505(b)(2) pathway, and established commercial operations with strong relationships with healthcare professionals and patient advocacy groups. The company relies on third-party contract manufacturing organizations (CMOs) for product manufacturing, which reduces capital investment and provides flexibility.

The company's core business model involves generating revenue primarily through product sales and royalties from its commercial rare disease products. These products are distributed to patients via specialty pharmacies, which also handle customer service and reimbursement activities. Revenue recognition for product sales occurs upon delivery to the wholesaler, where the wholesaler takes control, title, and risk of loss. Licensing revenue is recognized when milestone conditions are achieved and a significant revenue reversal is not probable. The company's revenues and accounts receivable are highly concentrated, with AnovoRx representing 84.6% ¹ of net revenues for the year ended December 31, 2025, and 88.4% ² of net accounts receivable as of December 31, 2025.

Eton's commercial product portfolio includes INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI™, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX® is a biologic product approved for severe primary insulin-like growth factor 1 deficiency (SPIGFD) in children, acquired and launched in December 2024. ALKINDI SPRINKLE® is an FDA-approved granule hydrocortisone for Adrenocortical Insufficiency (AI) in children under 17, protected by patents extending to 2032, 2033, and 2034. KHINDIVI™ is an FDA-approved oral solution formulation of hydrocortisone for AI in pediatric patients five years and older, protected by two issued patents extending to 2043. GALZIN® is an FDA-approved maintenance treatment for Wilson disease, acquired in December 2024 and commercialized in the U.S. in March 2025. PKU GOLIKE® is a medical formula for phenylketonuria (PKU), with U.S. rights acquired in March 2024. Carglumic Acid, Betaine Anhydrous, and Nitisinone are FDA-approved generic versions for NAGS deficiency, homocystinuria, and tyrosinemia type 1, respectively.

In terms of late-stage development, Eton has ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector. ET-600, for Diabetes Insipidus, had its NDA accepted for review by the FDA in July 2025 with a PDUFA target action date of February 25, 2026, and is protected by a patent extending to 2044. Amglidia® (glyburide oral suspension) is being developed for neonatal diabetes mellitus, with U.S. rights licensed in November 2024, and has Orphan Drug Designation from the FDA. ET-700, for Wilson Disease, is scheduled for a proof-of-concept PET study in 2026. ET-800 is an injectable liquid hydrocortisone for the hospital market, and ZENEO® hydrocortisone autoinjector is a needle-free autoinjector for adrenal crisis.

For the fiscal year ended December 31, 2025, Eton Pharmaceuticals reported total net revenues of $79.950 million ³, a significant increase from $39.011 million ⁴ in 2024. Product sales and royalties, net, were $76.664 million ⁵ in 2025, up from $38.511 million ⁶ in 2024. Licensing revenue was $3.286 million ⁷ in 2025, compared to $0.500 million ⁸ in 2024. The company generated a gross profit of $42.740 million ⁹ in 2025, with a gross margin of 53.5% ¹⁰, which decreased from a gross profit of $23.411 million ¹¹ and a gross margin of 60.0% ¹² in 2024. Operating expenses totaled $43.584 million ¹³ in 2025, leading to a loss from operations of $0.844 million ¹⁴. Net loss for the year was $4.601 million ¹⁵, resulting in a basic and diluted net loss per share of $0.17 ¹⁶. As of December 31, 2025, cash and cash equivalents stood at $25.942 million ¹⁷, total assets were $92.114 million ¹⁸, and total liabilities were $65.960 million ¹⁹. The company had long-term debt, net of discount and including accrued fees, of $21.769 million ²⁰.

Comparing 2025 to 2024, total net revenues increased by $40.939 million [3,4], or 104.9%, driven by a $38.153 million [5,6] increase in product sales and royalties, net, and a $2.786 million [7,8] increase in licensing revenue. The increase in product sales was primarily due to higher sales volume of INCRELEX®, ALKINDI SPRINKLE®, and GALZIN® products. The gross margin decreased from 60.0% ¹² in 2024 to 53.5% ¹⁰ in 2025, mainly due to higher commissions related to the out-licensing of INCRELEX® rights outside the U.S. Research and development expenses increased from $3.255 million ²¹ in 2024 to $7.765 million ²² in 2025, primarily due to a $2.2 million ²³ NDA filing fee for ET-600 and increased development activities for ET-700 and ET-800. General and administrative expenses rose from $22.753 million ²⁴ in 2024 to $35.819 million ²⁵ in 2025, attributed to increased product advertising and promotional expenses, higher stock-based compensation, and an increase in general and administrative headcount. Net cash from operating activities increased significantly from $0.969 million ²⁶ in 2024 to $10.524 million ²⁷ in 2025, driven by higher cash collections from product sales, an FDA filing fee refund related to ET-400, and a licensing milestone payment. Net cash used in investing activities decreased from $40.014 million ²⁸ in 2024 to $0.333 million ²⁹ in 2025, as 2024 included one-time cash outflows for the acquisition of INCRELEX® and product licensing rights for GALZIN® and PKU GOLIKE®.

Significant operational developments during the period include the FDA approval of KHINDIVI™ in May 2025 as the only FDA-approved oral solution formulation of hydrocortisone for pediatric AI. In July 2025, ET-600's NDA was accepted for review by the FDA. The company out-licensed the commercial rights to INCRELEX® in territories outside the U.S. to Esteve Pharmaceuticals, S.A. in March 2025, receiving €4,000 ³⁰ to license the rights for up to ten years, with an option for Esteve to acquire international rights for up to €6,000 ³¹. In June 2025, the company purchased $11.540 million ³² in inventory in connection with the Ipsen S.A. asset purchase agreement, with payments structured in eight equal quarterly installments.

Eton Pharmaceuticals believes its existing cash and cash equivalents of $25.942 million ¹⁷ as of December 31, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these financial statements. This estimate is based on current assumptions regarding estimated sales and the ability to manage spending. However, the company acknowledges that projected estimates for product development spending, administrative expenses, and working capital requirements could change significantly, or growth could occur more rapidly or on a larger scale than expected, potentially requiring additional financing earlier than anticipated.

A major growth area for the company is the continued commercialization of its rare disease product portfolio, particularly with increased market penetration of INCRELEX®, ALKINDI SPRINKLE®, and GALZIN®, which contributed to increased sales volume in 2025. The recent FDA approval of KHINDIVI™ in May 2025, as the only FDA-approved oral solution formulation of hydrocortisone for pediatric adrenal insufficiency, is expected to drive future revenue, especially given its administration simplicity and dosing accuracy benefits for patients with swallowing difficulties or special administration needs.

Another significant growth vector is the advancement of its late-stage product candidates. ET-600, with a PDUFA target action date of February 25, 2026 ³³, is a key near-term opportunity, with launch inventory production scheduled for the first quarter of 2026 in anticipation of approval. The company recently held an ET-600 advisory meeting with leading pediatric endocrinology practitioners, indicating preparation for commercialization. Amglidia®, for neonatal diabetes mellitus, has Orphan Drug Designation from the FDA and is supported by five years of real-world safety and efficacy data from European patients, which will be used for Eton's NDA submission. The company paid $0.500 million ³⁴ to AMMTek upon receipt of FDA meeting minutes in July 2025 and could pay up to $1.850 million ³⁵ in additional milestones upon NDA acceptance and approval/first commercial sale.

The company is also pursuing ET-700 for Wilson Disease, with a proof-of-concept PET study scheduled for 2026 to validate its extended-release formulation, potentially supporting pivotal clinical trials in late 2026 or early 2027. ET-800, a ready-to-use injectable liquid hydrocortisone, targets the hospital market, and the ZENEO® hydrocortisone autoinjector is under development for adrenal crisis. The out-licensing of INCRELEX® commercial rights outside the U.S. to Esteve Pharmaceuticals, S.A. in March 2025, which included an upfront payment of €4,000 ³⁰ and potential future purchase options up to €6,000 ³¹, represents a strategic partnership to expand the product's reach and generate additional licensing revenue.

Operationally, the company anticipates that its general and administrative expenses will increase to support business growth, particularly in sales and marketing activities and additional personnel. This aligns with the observed increase in G&A expenses in 2025 due to product advertising, promotional expenses, and headcount additions. The company's reliance on third-party contract manufacturing organizations (CMOs) is a core part of its operational strategy, reducing capital investment and providing flexibility. However, this also means the company is dependent on these CMOs for compliance with GMPs and maintaining adequate quality control and capacity.

Planned capital allocation includes continued investment in research and development, as evidenced by the $7.765 million ²² R&D expenses in 2025, which included a $2.2 million ²³ NDA filing fee for ET-600 and increased development activities for ET-700 and ET-800. The company's debt structure includes quarterly principal payments of $3.000 million ³⁶ beginning in May 2026, with a final principal payment of $9.000 million ³⁷ due at maturity in December 2027, under its expanded credit facility of $30.000 million ³⁸. The company does not plan to pay any cash dividends in the foreseeable future, intending to reinvest all earnings to cover operating costs and maintain competitiveness.

Structural headwinds and execution risks management explicitly flagged include the potential adverse effects of the Inflation Reduction Act and related Medicare reforms on product prices and demand. The company's participation in U.S. government price reporting and discount programs, such as Medicaid Drug Rebate Program, 340B, VA/FSS, and TRICARE, imposes complex and evolving obligations that could affect net prices and expose the company to significant liabilities. Third-party coverage and reimbursement, including PBM practices, formulary controls, and utilization management, may constrain future revenues. The company also faces risks related to government scrutiny of patient services and assistance programs, which could lead to curtailment and reduced patient access.

Eton Pharmaceuticals operates in a dynamic environment with several material risks. Macroeconomic risks include the potential adverse effects of the Inflation Reduction Act (IRA) and related Medicare reforms, which could impact product prices and demand through inflation-based rebates, changes to Medicare Part D benefits, and drug price negotiation programs. The company's participation in U.S. government price reporting and discount programs, such as Medicaid Drug Rebate Program, 340B, VA/FSS, and TRICARE, exposes it to complex and evolving obligations, with noncompliance potentially leading to significant refunds, civil monetary penalties, contractual damages, and exclusion from government programs. Third-party coverage and reimbursement, including formulary controls and utilization management by Pharmacy Benefit Managers (PBMs), may constrain future revenues, and inadequate or restrictive coverage could adversely affect sales and profitability. Operational risks include the company's complete dependence on third-party contract manufacturers, where failures in manufacturing approval, insufficient quantities, or quality issues could halt or delay commercialization. Supply-chain disruptions, capacity constraints, quality issues, and geopolitical developments, particularly concerning single-source or limited-source suppliers and those in higher-risk geographies like the People's Republic of China, could limit the ability to obtain materials or manufacture and distribute products. Cybersecurity threats, including cyber attacks and data breaches, pose a significant risk to information technology systems, potentially causing operational interruptions, misappropriation of confidential information, and substantial expenditures to remedy, despite the company carrying cyber liability insurance. The use of artificial intelligence-based software also presents risks of flawed algorithms, insufficient data, and the release of confidential information. Competitive risks stem from the intensely competitive biotechnology and pharmaceutical industries, with competitors potentially developing comparable products more rapidly, especially through the 505(b)(2) or 505(j) pathways, which could reduce market opportunity and force price reductions. Regulatory risks include the lengthy and expensive FDA approval process, with no guarantee of timely approval, and the possibility that product candidates may not satisfy the requirements for the 505(b)(2) pathway, leading to longer timelines and higher costs. Post-approval, the company is subject to ongoing regulatory review, including GMP compliance, and risks of product labeling restrictions, market withdrawal, and penalties for non-compliance. Legal risks include potential product liability lawsuits, which could result in substantial liabilities not fully covered by insurance, and patent infringement lawsuits from third parties, which could delay or prevent commercialization and incur significant costs.

Management's overall tone emphasizes Eton Pharmaceuticals' commitment to becoming a leading pharmaceutical company focused on rare diseases, highlighting its unique ability to identify, acquire, and advance products through the development and regulatory process. They stress the importance of leveraging their business development experience, regulatory expertise, particularly within the 505(b)(2) pathway, and established commercial operations to quickly and effectively commercialize new products. Management explicitly states their belief that current revenues and cash flows from the product portfolio will be sufficient for at least the next twelve months ³⁹. Key strategic priorities for the period ahead include driving market penetration for existing commercial products like INCRELEX®, ALKINDI SPRINKLE®, and GALZIN®, and advancing late-stage product candidates such as ET-600, which has a PDUFA target action date of February 25, 2026 ³³, and Amglidia®. They also emphasize the importance of strategic partnerships, as demonstrated by the out-licensing of INCRELEX® rights outside the U.S. to Esteve Pharmaceuticals, S.A., which generated €4,000 ³⁰ in licensing fees and potential future purchase options up to €6,000 ³¹. Management acknowledges the need for increased general and administrative expenses to support business growth, particularly in sales and marketing and personnel. They also highlight the ongoing commitment to research and development, with $7.765 million ²² spent in 2025, including a $2.2 million ²³ NDA filing fee for ET-600.